Skip to main content
. 2011 Jun 27;13(3):R105. doi: 10.1186/ar3386

Table 2.

Development of ATI by MTX treatment in RA and SpA patientsa

RA (n = 17) SpA (n = 91)

MTX treatment ATIpos ATIneg P value ATIpos ATIneg P value
MTX+ 3 6 0 25
MTX- 4 4 0.8 14 52 0.03

aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis; SpA: spondyloarthritis; MTX: methotrexate. Data represent number of patients in each category.